125 related articles for article (PubMed ID: 15155548)
21. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
Hirani VN; Raucy JL; Lasker JM
Drug Metab Dispos; 2004 Dec; 32(12):1462-7. PubMed ID: 15448116
[TBL] [Abstract][Full Text] [Related]
22. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
23. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
24. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation.
Stresser DM; Kupfer D
Drug Metab Dispos; 1998 Sep; 26(9):868-74. PubMed ID: 9733665
[TBL] [Abstract][Full Text] [Related]
25. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
Usmani KA; Karoly ED; Hodgson E; Rose RL
Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
[TBL] [Abstract][Full Text] [Related]
26. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
27. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.
Hamitouche S; Poupon J; Dreano Y; Amet Y; Lucas D
Toxicol Lett; 2006 Dec; 167(3):221-30. PubMed ID: 17084997
[TBL] [Abstract][Full Text] [Related]
28. Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4.
Li XQ; Weidolf L; Simonsson R; Andersson TB
J Pharmacol Exp Ther; 2005 Nov; 315(2):777-87. PubMed ID: 16093273
[TBL] [Abstract][Full Text] [Related]
29. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.
Ko JW; Desta Z; Soukhova NV; Tracy T; Flockhart DA
Br J Clin Pharmacol; 2000 Apr; 49(4):343-51. PubMed ID: 10759690
[TBL] [Abstract][Full Text] [Related]
30. Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation.
Emoto C; Iwasaki K
Xenobiotica; 2007 Jun; 37(6):592-603. PubMed ID: 17614006
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
Ueng YF; Hsieh CH; Don MJ
Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
[TBL] [Abstract][Full Text] [Related]
32. Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: focusing on CYP2A6.
Narimatsu S; Nakanishi R; Hanioka N; Saito K; Kataoka H
Chem Biol Interact; 2011 Nov; 194(2-3):120-6. PubMed ID: 21964418
[TBL] [Abstract][Full Text] [Related]
33. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
[TBL] [Abstract][Full Text] [Related]
34. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
[TBL] [Abstract][Full Text] [Related]
35. Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19.
Zhang W; Ramamoorthy Y; Tyndale RF; Glick SD; Maisonneuve IM; Kuehne ME; Sellers EM
Drug Metab Dispos; 2002 Jun; 30(6):663-9. PubMed ID: 12019193
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
37. Diazinon is activated by CYP2C19 in human liver.
Kappers WA; Edwards RJ; Murray S; Boobis AR
Toxicol Appl Pharmacol; 2001 Nov; 177(1):68-76. PubMed ID: 11708902
[TBL] [Abstract][Full Text] [Related]
38. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes.
Kobayashi K; Kogo M; Tani M; Shimada N; Ishizaki T; Numazawa S; Yoshida T; Yamamoto T; Kuroiwa Y; Chiba K
Drug Metab Dispos; 2001 Jan; 29(1):36-40. PubMed ID: 11124227
[TBL] [Abstract][Full Text] [Related]
39. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
40. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
